PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

@article{Fujita2006PTENAC,
  title={PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer},
  author={Shin-ichi Fujita and Hiroyoshi Doihara and Keisuke Kawasaki and Daisuke Takabatake and Hidekazu Hamamatsu Takahashi and Kazuhiro Washio and Kazunori Tsukuda and Yutaka Ogasawara and Nobuyuki Shimizu},
  journal={British Journal of Cancer},
  year={2006},
  volume={94},
  pages={247 - 252}
}
Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient's prior treatment, but even when patients are selected on the basis of HER2/neu gene amplification, the single-agent response rate ranges from 12 to 30% and few patients respond to trastuzumab monotherapy. Here, we propose PTEN as a predictive… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Similar Papers

Loading similar papers…